Marek T.
- Country
- Czechia
- Department
- I Internal clinic
Research Overview
- INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Evaluation of Epcoritamab in Combination with Chemotherapeutic Agents in B-cell Non-Hodgkin Lymphoma: A Phase 1b/2 Open-Label Study
- Phase 3 Randomized Study of Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
Data & Insights
Has run more than one trial at 279 of 454 partner sites.
Specializations
Lymphoma Research
Extensive focus on treating various forms of B-cell lymphomas, with particular emphasis on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Investigation includes novel therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- Non-Hodgkin's Lymphoma Treatment Protocols
- Mantle Cell Lymphoma Therapies
- T-Cell Lymphoma Interventions
Leukemia Studies
Specialized research in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), exploring innovative treatment combinations and targeted therapies.
- BTK Inhibitor Treatments
- Combination Therapy Approaches
- Novel Agent Development
Blood Disorders
Research focusing on immune thrombocytopenia (ITP) and other blood-related conditions, investigating new therapeutic options and treatment combinations.
- Immunoglobulin Therapy
- Platelet Disorder Management
- Immunological Interventions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.